Oral alternatives that are FDA-approved Foundayo (orforglipron) Eli Lillys Foundayo was approved by the FDA on April 1, 2026 for weight management in adults with obesity or overweight with at least one weight-related condition
Although low-grade inflammation has been evidenced in the depressed patient population and anti-inflammatory drugs showed encouraging results in pilot studies, anti-inflammatory drugs are not indicated as monotherapy or add-on treatment for depression yet (see for review [138])
If your periods are historically irregular, achieving a healthier weight can work in your favor by encouraging more regular cycles
Although the precise mechanism remains unclear to date, these drugs hold potential as therapeutic options for GA patients with FA metabolism disorders (97)
eficacia demostrada en el 62% de los sujetos en ensayo
In 2023, the United States Food and Drug Administration (FDA) approved the highest number of new drugs in history (61), marking a record year in pharmaceutical development
